NASHUA, N.H., Dec. 10 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that two U.S. Patents, No. 7,298,877 and No. 7,308,126, have recently been granted to the Company by the United States Patent and Trademark Office.
“These patent grants demonstrate our on-going commitment to broadening and protecting our intellectual property, and represent an important addition to our portfolio of CAD product and technology patents,” said Ken Ferry, President and Chief Executive Officer of iCAD. “The first patent provides an information fusion method for multiple indicators of cancer by using a specific method of combining lesion information, while the second patent addresses improved clinical workflow.”
These patent awards bring the number of issued patents in 2007 to four, which includes two patents issued in June related to CAD billing workflow support and CAD for virtual colonoscopy.
iCAD offers high-performance CAD solutions for both digital and film-based mammography systems. Additionally, iCAD is developing CAD solutions for use with virtual colonoscopy to improve the detection of colonic polyps. iCAD’s systems are based on sophisticated algorithms that analyze the data, automatically identifying and marking suspicious regions in the images. The result is earlier detection of hard-to-find cancers, improved workflow for radiologists and higher quality patient care.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com.
ddeptula@icadmed.com
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn &
Associates at 212-838-3777 x6604 or via email at icad@lhai.comicad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
CONTACT: Darlene Deptula-Hicks, EVP and CFO of iCAD, Inc., +1-603-882-5200
x7944, ddeptula@icadmed.com; iCAD Investor Relations: Anne Marie Fields of
Lippert/Heilshorn & Associates, +1-212-838-3777 x6604, icad@lhai.com; iCAD
Public Relations: Wendy Ryan of Schwartz Communications, +1-781-684-0770,
icad@schwartz-pr.com
Web site: http://www.icadmed.com/
